Skip to main content
. 2021 Oct 20;22(21):11342. doi: 10.3390/ijms222111342

Figure 3.

Figure 3

Mean percentage BMD loss at week 24 (lumbar spine) in women treated with different doses of gonadotropin-releasing hormone (GnRH) antagonist (150 mg elagolix once daily, 200 mg elagolix twice daily; 75 mg, 100 mg and 200 mg linzagolix once daily; and 40 mg relugolix plus ABT once daily).